Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer

Gynecologic Oncology

Volumn 122, Issue 3, 2011, Pages 532-535

  Fauci, Janelle M ^a   Whitworth, Jenny M ^a   Schneider, Kellie E ^a   Subramaniam, Akila ^a   Zhang, Bin ^a   Frederick, Peter J ^a   Kilgore, Larry C ^a   Straughn Jr , J Michael ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Dose intensity; Ovarian cancer; Treatment

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONFLICT; CONFLICT MANAGEMENT; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEUTROPENIA; OVARY CANCER; PATIENT TRANSPORT; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RELATIVE DOSE INTENSITY; RETROSPECTIVE STUDY; SURVIVAL; THERAPY DELAY; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TAXOIDS; YOUNG ADULT;

EID: 80051548582     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.05.023     Document Type: Article

References (25)

1. American Cancer Society. Cancer facts and figures 2010 2010 American Cancer Society Atlanta
2. J.P. Curtin, R. Malik, E.S. Venkatraman, R.R. Barakat, and W.J. Hoskins Stage IV ovarian cancer: impact of surgical debulking Gynecol Oncol 64 1997 9 12 (Pubitemid 27026949)
3. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6 (Pubitemid 26012496)
4. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Gynecology Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200 (Pubitemid 46606249)
5. G.A. Omura, M.F. Brady, H.D. Homesley, E. Yordan, F.J. Major, and H.J. Buschbaum Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecology Oncology Group experience J Clin Oncol 9 1991 1138 1150
6. W.M. Hryniuk The importance of dose intensity in the outcome of chemotherapy Important advances in oncology 1988 1988 JB Lippincott Co Philadelphia, Pa 121 141
7. G.H. Lyman, D.C. Dale, J. Friedberg, J. Crawford, and R.I. Fisher Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study J Clin Oncol 22 2004 4302 4311 (Pubitemid 41185151)
8. I. Chirivella, B. Bermejo, A. Insa, A. Perez-Fidalgo, A. Magro, and S. Rosello Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients Breast Cancer Res Treat 114 2009 479 484
9. L. Levin, and W.M. Hryniuk Dose intensity analysis of chemotherapy regimens in ovarian carcinoma J Clin Oncol 5 1987 756 767 (Pubitemid 17120253)
10. L. Levin, R. Simon, and W. Hryniuk Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis J Natl Cancer Inst 85 1993 1732 1742 (Pubitemid 23320843)
11. D.R. Budman, D.A. Berry, and C.T. Cirrincione Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer J Natl Cancer Inst 90 1998 1205 1211 (Pubitemid 28407086)
12. J. Chang Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer Eur J Cancer 36 2000 S11 S14
13. M.L. Citron, D.A. Berry, and C. Cirrincione Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741 J Clin Oncol 21 2003 1431 1439 (Pubitemid 46594092)
14. M.J. Piccart, L. Biganzoli, and A. Di Leo The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer 36 2000 S4 S10
15. W.C. Wood, D.R. Budman, and A.H. Korzun Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 330 1994 1253 1259
16. G. Bonadonna, M. Zambetti, and P. Valagussa Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 1995 901 906
17. W.P. McGuire, W.J. Hoskins, and M.F. Brady A phase III trial of dose intense (DI) versus standard dose (SD) cisplatin (CDDP) and cytoxan (CTX) Advanced ovarian cancer (AOC). Proc ASCO 11:abstr 718 1992
18. S.B. Kaye, C.R. Lewis, J. Paul, I.D. Duncan, H.K. Gordom, and H.C. Kitchener Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 8815 1992 329 333
19. D.I. Jodrell, M.J. Egorin, R.M. Canetta, P. Langenberg, E.P. Goldbloom, and J.N. Burroughs Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer J Clin Oncol 4 1992 520 528
20. A. du Bois, H.J. Lück, and W. Meier A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 17 2003 1320 1329
21. G.H. Lyman, D.C. Dale, and J. Crawford Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices J Clin Oncol 21 2003 4524 4531 (Pubitemid 46594022)
22. B.K. Link, G.T. Budd, and S. Scott Delivering adjuvant chemotherapy to women with early-stage breast cancer: current patterns of care Cancer 92 2001 1354 1367 (Pubitemid 32947818)
23. D. Crivellari, M. Bonetti, and M. Castiglione-Gertsch Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group trial VII J Clin Oncol 18 2000 1412 1422 (Pubitemid 30205386)
24. E.C. Dees, S. O'Reilly, and S.N. Goodman A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer Cancer Invest 18 2000 521 529 (Pubitemid 30485668)
25. J. Crawford Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy Pharmacotherapy 8 Pt 2 2003 15S 19S (Pubitemid 36904014)